OverviewSuggest Edit

Seres Therapeutics is a microbiome therapeutics platform company which engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology to treat multiply recurrent Clostridium difficile infection. The Company also develops a number of other product candidates for treatment of various diseases, including ulcerative colitis, Clostridium difficile infection, inflammatory bowel disease, etc.

TypePublic
Founded2010
HQCambridge, US
Websiteserestherapeutics.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2018)145(+6%)
Revenue (FY, 2018)$28.3 M(-11%)
Share Price (Jun 2019)$3.2 (-2%)

Key People/Management at Seres Therapeutics

Roger Pomerantz

Roger Pomerantz

President, Chief Executive Officer, and Chairman of the Board of Directors
John Aunins

John Aunins

Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer
David Cook

David Cook

Executive Vice President of Research & Development and Chief Scientific Officer
Thomas DesRosier

Thomas DesRosier

Executive Vice President, Chief Legal Officer and Secretary
Matthew Henn

Matthew Henn

Senior Vice President, Head of Drug Discovery & Bioinformatics
Carol Lewis-Cullinan

Carol Lewis-Cullinan

Vice President and Head of Clinical Operations
Show more

Seres Therapeutics Office Locations

Seres Therapeutics has an office in Cambridge
Cambridge, US (HQ)
200 Sidney St
Show all (1)

Seres Therapeutics Financials and Metrics

Seres Therapeutics Revenue

Seres Therapeutics's revenue was reported to be $28.27 m in FY, 2018
USD

Revenue (Q1, 2019)

260.0k

Net income (Q1, 2019)

(24.3m)

EBIT (Q1, 2019)

(24.6m)

Market capitalization (10-Jun-2019)

130.3m

Closing stock price (10-Jun-2019)

3.2

Cash (31-Mar-2019)

53.6m
Seres Therapeutics's current market capitalization is $130.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

21.8m32.1m28.3m

General and administrative expense

16.8m32.6m34.0m32.6m

R&D expense

38.1m82.0m89.5m96.0m

Operating expense total

54.9m114.6m123.5m128.6m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019

Revenue

2.7m3.0m13.0m3.0m3.0m23.0m4.0m4.6m260.0k

General and administrative expense

3.6m4.7m7.2m9.0m8.0m8.8m8.4m8.1m8.8m8.7m7.5m

R&D expense

8.8m9.9m15.4m22.2m24.1m20.1m23.1m22.2m23.5m24.1m22.9m

Operating expense total

12.3m14.6m22.6m31.1m32.1m28.9m31.4m30.3m32.2m32.7m31.9m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

73.9m54.5m36.1m85.8m

Inventories

2.5m5.1m

Current Assets

207.6m198.4m155.1m92.7m

PP&E

7.8m36.1m32.9m26.3m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019

Cash

36.3m69.7m193.2m59.8m55.6m41.9m33.6m46.0m47.2m58.0m53.6m

Accounts Receivable

6.7m

Current Assets

94.1m222.4m306.8m217.1m208.4m192.3m176.1m176.6m126.5m101.5m67.8m

PP&E

3.3m4.5m16.1m27.0m34.6m36.1m34.8m33.7m31.5m29.9m24.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(54.8m)(91.6m)(89.4m)(98.9m)

Depreciation and Amortization

728.0k4.2m7.3m7.9m

Inventories

(2.5m)(2.6m)

Accounts Payable

2.7m3.6m(856.0k)(353.0k)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019

Net Income

(20.5m)(35.1m)(19.7m)(27.9m)(66.3m)(25.5m)(53.5m)(60.4m)(27.9m)(55.7m)(24.3m)

Depreciation and Amortization

212.0k394.0k2.5m3.5m5.4m1.9m3.9m2.0m

Accounts Payable

(141.0k)532.0k5.8m4.5m84.0k5.6m(3.7m)(2.5m)(1.4m)(1.5m)(2.5m)

Cash From Operating Activities

(18.0m)(29.3m)64.7m(51.3m)(54.9m)(26.8m)
USDY, 2019

Financial Leverage

-1.5 x
Show all financial metrics

Seres Therapeutics Online and Social Media Presence

Embed Graph

Seres Therapeutics News and Updates

BRIEF-Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc

* Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc As Of April 10, 2018 - SEC Filing Source text (https://bit.ly/2GSzKlq) Further company coverage: (Reuters.Briefs@thomsonreuters.com…

Seres Therapeutics Frequently Asked Questions

  • When was Seres Therapeutics founded?

    Seres Therapeutics was founded in 2010.

  • Who are Seres Therapeutics key executives?

    Seres Therapeutics's key executives are Roger Pomerantz, John Aunins and David Cook.

  • How many employees does Seres Therapeutics have?

    Seres Therapeutics has 145 employees.

  • What is Seres Therapeutics revenue?

    Latest Seres Therapeutics annual revenue is $28.3 m.

  • What is Seres Therapeutics revenue per employee?

    Latest Seres Therapeutics revenue per employee is $194.9 k.

  • Who are Seres Therapeutics competitors?

    Competitors of Seres Therapeutics include Sosei Heptares, Celgene and Anavex.

  • Where is Seres Therapeutics headquarters?

    Seres Therapeutics headquarters is located at 200 Sidney St, Cambridge.

  • Where are Seres Therapeutics offices?

    Seres Therapeutics has an office in Cambridge.

  • How many offices does Seres Therapeutics have?

    Seres Therapeutics has 1 office.